Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas—A Preliminary Study
K Skubisz, K Dąbkowski, E Samborowska… - Cancers, 2023 - mdpi.com
Simple Summary Pancreatic cancer is a significant problem worldwide. Most cancers are
diagnosed at an advanced stage. Limited knowledge of the pathogenesis of pancreatic …
diagnosed at an advanced stage. Limited knowledge of the pathogenesis of pancreatic …
Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study
Background Early detection of pancreatic ductal adenocarcinoma (PDAC) may improve the
prognosis of patients. This study was to identify metabolic features of PDAC and to discover …
prognosis of patients. This study was to identify metabolic features of PDAC and to discover …
[HTML][HTML] Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites
Purpose pancreatic adenocarcinoma is the fourth leading cause of cancer related deaths
due to its aggressive behavior and poor clinical outcome. There is a considerable variability …
due to its aggressive behavior and poor clinical outcome. There is a considerable variability …
Discovery of pancreatic adenocarcinoma biomarkers by untargeted metabolomics
A Martín-Blázquez, C Jiménez-Luna, C Díaz… - Cancers, 2020 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal
cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection …
cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection …
Untargeted LC-HRMS-based metabolomics for searching new biomarkers of pancreatic ductal adenocarcinoma: A pilot study
S Rios Peces, C Diaz Navarro… - … Life Sciences R&D, 2017 - journals.sagepub.com
Pancreatic ductal adenocarcinoma is one of the most lethal tumors since it is usually
detected at an advanced stage in which surgery and/or current chemotherapy have limited …
detected at an advanced stage in which surgery and/or current chemotherapy have limited …
Evaluating metabolite-based biomarkers for early diagnosis of pancreatic cancer: a systematic review
G Perazzoli, OM García-Valdeavero, M Peña, J Prados… - Metabolites, 2023 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year
survival rates around 10%. The only curative option remains complete surgical resection, but …
survival rates around 10%. The only curative option remains complete surgical resection, but …
Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC
J Xiang, L Liu, W Wang, H Xu, C Wu, J Xu, C Liu… - Cancer letters, 2015 - Elsevier
Pancreatic cancer is currently one of the deadliest solid malignancies and pancreatic ductal
adenocarcinoma (PDAC) is the most common type of pancreatic cancer. In the past decade …
adenocarcinoma (PDAC) is the most common type of pancreatic cancer. In the past decade …
Metabolomics in pancreatic cancer biomarkers research
J Tumas, K Kvederaviciute, M Petrulionis, B Kurlinkus… - Medical Oncology, 2016 - Springer
Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000
deaths a year from this disease are observed in European Union alone. The only possibly …
deaths a year from this disease are observed in European Union alone. The only possibly …
Analytical metabolomics-based approaches to pancreatic cancer
IM Di Gangi, U Vrhovsek, V Pazienza… - TrAC Trends in Analytical …, 2014 - Elsevier
We provide a comprehensive review of the analytical technologies applied in pancreatic
cancer (PC) research, investigating tumor-associated metabolites identified as possible new …
cancer (PC) research, investigating tumor-associated metabolites identified as possible new …
A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma
RIR Macias, L Muñoz-Bellvís, A Sánchez-Martín… - Cancers, 2020 - mdpi.com
The diagnosis of adenocarcinomas located in the pancreas head, ie, distal
cholangiocarcinoma (dCCA) and pancreatic ductal adenocarcinoma (PDAC), constitutes a …
cholangiocarcinoma (dCCA) and pancreatic ductal adenocarcinoma (PDAC), constitutes a …